(Total Views: 596)
Posted On: 10/19/2024 11:30:38 AM
Post# of 154062
Hi ohm20, first off want to thank you for information like this, I dont have a medical background and this helps me understand these trials and research papers better.
Being they didnt have the exclusion for the ccr5 delta 32 double allele deletion, this potentially caused less ccr5 receptors to be available for leronlimab to inhibit and possibly showed a lower efficacy in the overall trial? In other words, its possible if this exclusion was in place, the results could have shown better efficacy?
Being they didnt have the exclusion for the ccr5 delta 32 double allele deletion, this potentially caused less ccr5 receptors to be available for leronlimab to inhibit and possibly showed a lower efficacy in the overall trial? In other words, its possible if this exclusion was in place, the results could have shown better efficacy?
(4)
(0)
The fault-finder will find faults even in paradise. -Henry David Thoreau
